DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats

Biological Chemistry

Volumn 392, Issue 3, 2011, Pages 209-215

  Freyse, Ernst Joachim ^a   Berg, Sabine ^a   Kohnert, Klaus Dieter ^a   Heinke, Peter ^a   Salzsieder, Eckhard ^a  

^a Institut fur Diabetes 'Gerhardt Katsch'   (Germany)

Author keywords

Dipeptidyl peptidase 4 inhibitor; GIP; GLP 1; Incretin actions; Intravenous glucose tolerance test (IVGTT); Rat

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; DRUG DERIVATIVE; ISOLEUCINE; ISOLEUCYL THIAZOLIDIDE; ISOLEUCYL-THIAZOLIDIDE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; ANIMAL; BLOOD; DRUG POTENTIATION; GLUCOSE TOLERANCE TEST; ORAL DRUG ADMINISTRATION; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG SYNERGISM; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; INCRETINS; INSULIN; ISOLEUCINE; MALE; RATS; RATS, WISTAR; THIAZOLES;

EID: 79953645381     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2011.027     Document Type: Article

References (19)

1. Berg, S., Heinke, P., Salzsieder, E., Kohnert, K.D., and Freyse, E.J. (2008). A simple test to differentiate GLP-1 and GIP effects on the endocrine pancreas. 3rd International Symposium 'The Metabolic Syndrome - a postprandial disease'. Diabetes Metab. Heart 7, 57.
2. Conard, V. (1955). Mesure de l'assimilation du glucose: Bases théoriques et application cliniques. Acta Gastro-Enterol. Belg. 18, 803-845.
3. Deacon, C.F., Nauck, M.A., Toft-Nielsen, M., Pridal, L., Willms, B., and Holst, J.J. (1995a). Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44, 1126-1131.
4. Deacon, C.F., Johnsen, A.H., and Holst, J.J. (1995b). Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952-957.
5. Deacon, C.F., Pridal, L., Klarskov, L., Olesen, M., and Holst, J.J. (1996). Glucagon-like peptide 1 undergoes differential tissuespecific metabolism in the anesthetized pig. Am. J. Physiol. 271, E458-E464.
6. Deacon, C.F., Hughes, T.E., and Holst, J.J. (1998). Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon- like peptide 1 in the anesthetized pig. Diabetes 47, 764-769. (Pubitemid 28201806)
7. Deacon, C.F., Nauck, M.A., Meier, J., Hucking, K., and Holst, J.J. (2000). Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 85, 3575-3581.
8. Deacon, C.F., Danielsen, P., Klarskov, L., Olesen, M., and Holst, J.J. (2001). Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50, 1588-1597. (Pubitemid 33639599)
9. Deacon, C.F., Plamboeck, A., Moller, S., and Holst, J.J. (2002). GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am. J. Physiol. Endocrinol. Metab. 282, E873-E879. (Pubitemid 34654749)
10. Deacon, C.F., Plamboeck, A., Rosenkilde, M.M., de Heer, J., and Holst, J.J. (2006). GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Am. J. Physiol. Endocrinol. Metab. 291, E468-E475. (Pubitemid 44352251)
11. Elahi, D., Egan, J.M., Shannon, R.P., Meneilly, G.S., Khatri, A., Habener, J.F., and Andersen, D.K. (2008). GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity 16, 1501-1509. (Pubitemid 351915102)
12. Gault, V.A., Parker, J.C., Harriott, P., Flatt, P.R., and O'Harte, F.P. (2002). Evidence that the major degradation product of glucosedependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J. Endocrinol. 175, 525-533. (Pubitemid 35414398)
13. Kieffer, T.J., McIntosh, C.H., and Pederson, R.A. (1995). Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585-3596.
14. Kutscherauer, G., Bedorf, A., Nicolaus, M., Göke, B., and Schirra, J. (2009). The DPP-4 inhibitor sitagliptin improves glucose tolerance in type 2 diabetes mellitus involving GLP-1 dependent and GLP-1 independent pathways. Diabetologia 52 (Suppl. 1), p. S9, No. 5.
15. Meier, S., Hücking, K., Ritzel, R., Holst, J.J., Schmiegel, W.H., and Nauck, M.A. (2003). Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers. Horm. Metab. Res. 35, 551-556. (Pubitemid 37260421)
16. Meier, J.J., Gethmann, A., Nauck, M.A., Goetze, O., Schmitz, F., Deacon, C.F., Gallwitz, B., Schmidt, W.E., and Holst, J.J. (2006).The glucagon-like peptide 1 metabolite GLP-1 (9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am. J. Physiol. Endocrinol. Metab. 29, E1118-E1123. (Pubitemid 43847894)
17. Nauck, M.A., Heimesaat, M.M., Behle, K., Holst, J.J., Nauck, M.S., Ritzel, R., Hüfner, M., and Schmiegel, W.H. (2002). Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypo-glycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 87, 1239-1246. (Pubitemid 36121094)
18. Nikolaidis, L.A., Elahi, D., Shen, Y.T., and Shannon, R.P. (2005). Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289, H2401-H2408. (Pubitemid 41698549)
19. Simonsen, L., Holst, J.J., and Deacon, C.F. (2006). Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 49, 706-712. (Pubitemid 43357544)